Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 5, 2006, Pages 1156-1162

  Shang, Xi Liu ^a   Fan, Fan Hou ^a   Zhi, Jian Guo ^a   Nagai, Ryoji ^b   Wei, Ru Zhang ^a   Zhi, Qiang Liu ^a   Zhan, Mei Zhou ^a   Zhou, Mei ^a   Xie, Di ^a   Guo, Bao Wang ^a   Zhang, Xun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Advanced oxidation protein products; Atherosclerosis; Hypercholesterolemia; Inflammation; Oxidative stress

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN DERIVATIVE; SERUM ALBUMIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADVANCED GLYCATION END PRODUCT; LOW DENSITY LIPOPROTEIN; PLASMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BIOACCUMULATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RABBIT; ANIMAL; BLOOD; CELL PROLIFERATION; MACROPHAGE; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; ATHEROSCLEROSIS; BLOOD PROTEINS; CELL PROLIFERATION; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; INFLAMMATION; LIPOPROTEINS, LDL; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OXIDATION-REDUCTION; OXIDATIVE STRESS; RABBITS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646459653     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000214960.85469.68     Document Type: Article

References (34)

1. Ansari A, Kaupke CJ, Vaziri ND, Miller R, Barbari A. Cardiac pathology in patients with end-stage renal disease maintained on hemodialysis. Int J Artif Organs. 1993;16:31-36.
2. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis. 2003;41(5 Suppl):11-17.
3. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drucke T, Descamps-Latscha B. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol. 1998;161:2524-2532.
4. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, van Ypersole de Strihou C, Monnier VM, Witztum JL, Kurokawa K. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions: Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest. 1997;100:2995-3004.
5. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106:2212-2217.
6. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, London GM, Jungers P. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis. 2005;45:39-47.
7. Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res. 2002;51:597-604.
8. Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med. 2003;34:1563-1574.
9. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis. 2002;162:221-225.
10. Hou FF, Boyce J, Chertow GM, Kay J, Owen WF Jr. Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin. J Am Soc Nephrol. 1998;9:277-283.
11. Hou FF, Ren H, Owen WF Jr., Guo ZJ, Chen PY, Schmidt AM, Miyata T, Zhang X. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol. 2004;15:1889-1896.
12. Nagai R, Hayashi CM, Xia L, Takeya M, Horiuchi S. Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins. J Biol Chem. 2002;277:48905-48912. Epub 2002 Oct 10.
13. Capeillere-Blandin C, Gausson V, Descamps-Latscha B, Witko-Sarsat V. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim Biophys Acta. 2004;1689:91-102.
14. Holman RL, McGill HC Jr., Strong JC, and Geer JC. Techniques for studying atherosclerotic lesions. Lab Investig. 1958;7:42-47.
15. Lehr HA, Sagban TA, Ihling C, Zahringer U, Hungerer KD, Blumrich M, Reifenberg K, Bhakdi S. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation. 2001;104:914-920.
16. Zhou M, Chen Y, Yan DG, Zhao M, Liu SX, Pang ZJ, Wan J. Preparation and characterization of two monoclonal antibodies against oxidatively modified low density lipoprotein (O-LDL) and detection of O-LDL in serum in patients with coronary heart disease. Med Sci Res. 1997;25:445-449.
17. Shi ZR, Itzkowitz SH, Kim YS. A comparison of three immunoperoxidase techniques for antigen detection in colorectal carcinoma tissues. J Histochem Cytochem. 1988;36:317-322.
18. Shen H, Lu YD. Study on the quantitative method of immunohistochemistry. J Biomed Eng'. 1993;10:281-284.
19. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med. 1973;15:212-216.
20. Flohe L, Gunzler WA. Assays of glutathione peroxidase. Methods Enzymol. 1984;105:114-120.
21. Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation end-products promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med. 1995;1:447-456.
22. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest. 1999;104:103-113.
23. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest. 1996;97:1535-1544.
24. Guo ZJ, Hou FF, Liu SX, Zhang WR, Zhou ZM, Liu ZQ Proteins modified with glycation or oxidation products accelerate atherosclerosis in experimental hypercholesterolemic rabbits. Beijing Da Xue Xue Bao. 2004;36:127-130. Chinese.
25. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18:1272-1280.
26. Galle J, Seibold S. Has the time come to use antioxidant therapy in uraemic patients? Nephrol Dial Transplant. 2003;18:1452-1455.
27. Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol. 2003;14:1927-1939.
28. Mugge A, Brandes RP, Boger RH, Dwenger A, Bode-Boger S, Kienke S, Frolich JC, Lichtlen PR. Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 1994;24:994-998.
29. Scheuer H, Gwinner W, Hohbach J, Grone EF, Brandes RP, Malle E, Olbricht CJ, Walli AK, Grone HJ. Oxidant stress in hyperlipidemia-induced renal damage. Am J Physiol Renal Physiol. 2000;278:F63-F74.
30. Descamps-Latscha B, Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure. Kidney Int Suppl. 2001;78:S108-113.
31. Witko-Sarsat V, Gausson V, Nguyen AT, Touam M, Drueke T, Santangelo F, Descamps-Latscha B. AOPPs-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int. 2003;64:82-91.
32. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524-1538.
33. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial. 2002;15:329-337.
34. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999;85:753-766.